Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study

被引:0
作者
S Tanikawa
S Mori
K Ohhashi
H Akiyama
T Sasaki
H Kaku
K Hiruma
T Matsunaga
T Morita
H Sakamaki
机构
[1] Bone Marrow Transplantation Team,Pharmaceutical Development Department I
[2] Tokyo Metropolitan Komagome Hospital,undefined
[3] Teijin Limited,undefined
来源
Bone Marrow Transplantation | 2000年 / 26卷
关键词
hematopoietic stem cell transplantation; VOD; P-III-P;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatic veno-occlusive disease (VOD) is a major complication after hematopoietic stem cell transplantation (HSCT). Aetiological determinants, diagnosis and treatment remain unclear. Changes in coagulation-fibrinolysis parameters and N-terminal propeptide for type III procollagen (P-III-P) have been studied in patients with or without VOD after HSCT. We prospectively measured protein C activity, tissue plasminogen activator (t-PA), antithrombin III (AT-III), plasminogen activity (PLG), thrombin-antithrombin III (TAT), α2-plasmin inhibitor (α2-PI),fibrinogen (Fbg) and P-III-P in 44 consecutive adult patients undergoing allogeneic HSCT. Each parameter was determined before conditioning, on day 0 of HSCT and weekly for 5 weeks. Five of the 44 patients developed VOD at a median post HSCT of day 3 (range, day 3 to 12). On repeated analysis of variance (ANOVA), there were significant differences between patients with and without VOD in P-III-P (P < 0.0001), protein C (P < 0.0001), t-PA (P < 0.0001), PLG (P < 0.0001), AT-III(P < 0.0001), Fbg (P < 0.0001), α2-PI (P = 0.0002). Levels of P-III-P were significantly higher in patients with VOD than without VOD, before preparative chemotherapy (P < 0.005) and on days 0 and 7 (P < 0.001). On day 0, levels of t-PA were significantly higher in patients with VOD than without VOD (P < 0.05). On day 7, levels of protein C were significantly lower in patients with VOD than without VOD (P < 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with and without VOD in the levels of protein C. These results suggest P-III-P, t-PA and protein C are predictive markers for VOD after HSCT in adults. Moreover, the serum P-III-P level before start of conditioning might indicate patients at risk for developing VOD. Bone Marrow Transplantation (2000) 26, 881–886.
引用
收藏
页码:881 / 886
页数:5
相关论文
共 71 条
  • [1] McDonald GB(1984)Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology 4 116-122
  • [2] Sharma P(1989)Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation Transplantation 48 68-72
  • [3] Matthews DE(1993)Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 118 255-267
  • [4] Locasciulli A(1987)Veno-occlusive disease of the liver following bone marrow transplantation Transplantation 44 778-783
  • [5] Bacigalupo A(1992)Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation Bone Marrow Transplant 10 197-214
  • [6] Alberti A(1993)Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts development of venocclusive disease of the liver Blood 81 3458-3462
  • [7] McDonald GB(1991)High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma Bone Marrow Transplant 8 497-502
  • [8] Hinds MS(1993)N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin Bone Marrow Transplant 11 471-472
  • [9] Fisher LD(1994)Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Blood 83 3036-3040
  • [10] Jones RJ(1997)Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation Bone Marrow Transplant 19 915-920